Navigation Links
Helix Bioscience Appointed DNA Drug Sensitivity Testing Distributor for Genelex Corporation
Date:7/14/2010

SEATTLE and TULSA, Okla., July 14 /PRNewswire/ -- Genelex and Helix have announced a personalized prescribing strategic alliance to increase the availability of important new DNA Drug Sensitivity Tests such as Plavitest™ and Tamoxitest™. These tests and the GeneMedRx medication management software can save lives and healthcare dollars by allowing doctors to personalize their prescribing practices in order to prevent adverse medication outcomes, including treatment failures and dangerous side effects.

"Helix's knowledge and experience make them ideally suited to expand access to these products and contribute to improving prescribing safety," said Howard Coleman, Genelex Chief Executive Officer.

Helix is concentrating its initial efforts on Plavitest™ due to the recent FDA boxed warning placed on Plavix. Recent clinical research demonstrates that approximately one-third of patients are in varying degrees of treatment failure and could be at an increased risk of a recurrent heart attack, stroke or cardiovascular death. Plavitest identifies these patients so doctors can improve their medication regimen and chances for successful treatment. Plavix is the second leading selling prescription drug with over $8 billion in worldwide annual sales.

"We chose Genelex as our laboratory partner because of its proven track record in delivering DNA Drug Sensitivity Tests and the advantage of the GeneMedRx interpretive software," said Lincoln Maxwell, Helix chief executive officer. GeneMedRx closes the "interpretation gap" by providing prescribers actionable information to reduce the risk of treatment failures and adverse reactions based on the genetics and overall medication regimen of patients.

Helix Biosciences is a new company formed by a team of diagnostic industry professionals to bring the benefits of genetic testing to doctors and their patients.

Genelex (jen-uh-LEX) sells a combination of DNA Drug Sensitivity Testing and the GeneMedRx (jeen-med-r-x) software to doctors to help them choose the safest, most effective medicines for their patients. Wide adoption of these technologies is aimed at dramatically reduce deaths and injuries from adverse drug reactions, interactions and treatment failure.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Howard Coleman

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=44528


'/>"/>
SOURCE Genelex
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Helix BioPharma Reports On 2009 Annual General Meeting
2. Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
3. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. Helix BioPharma Corp. Announces Fiscal 2009 Results
5. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
6. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
7. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
8. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
9. SeqWrights Partnership with EraGen Biosciences Contributes to FDA Market Clearance Success
10. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
11. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
Breaking Medicine News(10 mins):